Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|The Lancet|2019Cited by 722
Placebo-controlled study in neuromyelitis optica—Ethical and design considerationsBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|Multiple Sclerosis Journal|2015Cited by 72
MOG-IgG1 and co-existence of neuronal autoantibodiesAmy Kunchok, Sean J Pittock, Eoin P. Flanagan et al.|Multiple Sclerosis Journal|2020Cited by 55
Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disordersVyanka Redenbaugh, Eoin P. Flanagan, Mayra Montalvo et al.|Multiple Sclerosis Journal - Experimental Translational and Clinical|2021Cited by 50
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Bruce Cree, Sean J Pittock et al.|Multiple Sclerosis and Related Disorders|2021Cited by 37